Revenue Increased 24.0% to $436.1 Million Gross Margin Increased 37.5% to $146.6 Million Net Income of $1.3 Million, or $0.01 per Diluted Share Adjusted Net Income per Diluted Share of. | August 12, 2021
Benchtop Lab Equipment Reports Strong Revenues and Earnings Company Continues to Invest In Its Bioprocessing Business BOHEMIA, NY / ACCESSWIRE / May 17, 2021 / Scientific Industries, Inc. (OTCQB:SCND)
MeiraGTx Reports First Quarter 2021 Financial and Operational Results
LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent progress.
“During the first quarter of 2021, we continued to advance our clinical and preclinical programs, as well as our proprietary cGMP manufacturing process. We are progressing rapidly with our riboswitch gene regulation technology platform and we are excited to share
in-vivo data later this year,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This will be an important year for MeiraGTx as the Company prepares for the initiation of two Phase 3 pivotal trials in X-linked retinitis pigmentosa and